Schizophrenia spectrum disorder
Conditions
Interventions
Olanzapine treatment group:N/A
Non-olanzapine treatment group:N/A
Sponsors
Nanchong Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. Patients with first-episode/recurrent schizophrenia; 2. The age ranged from 18 to 55 years; 3. The patient was able to understand and sign written informed consent. If the patient was incapacitated during the illness, written informed consent was required from the legal guardian.
Exclusion criteria
Exclusion criteria: 1. Patients with other psychiatric disorders who met DSM-IV diagnostic criteria; 2. Patients with unstable severe physical diseases: including diabetes mellitus, thyroid disease, hypertension, hyperlipidemia, cerebral infarction, heart disease, etc.; 3. Patients with severe, unstable physical conditions, including established diabetes, thyroid disease, hypertension, or high fat, who meet DSM-IV-TR criteria for alcohol and drug dependence (except nicotine dependence); 4. Patients with severe, unstable physical diseases, including diagnosed diabetes mellitus, thyroid disease, hypertension, hyperlipemia, epilepsy, febrile convulsions, and a history of constrictive glaucoma; 5. Patients who had used long-acting antipsychotic agents within the previous treatment interval (5-week interval for injectable risperidone); 6. Regularly use clozapine within one month before enrollment; Patients with recurrence had medication records within one month; 7. Patients who had been treated with ECT in the month before enrollment; 8. Patients who had suffered from or have suffered from the drug-induced malignant syndrome or severe tardive dyskinesia; 9. Patients with serious suicide attempts, or severe agitation; 10. Patients with obvious abnormal laboratory test results; 11. Patients who are unable to take medicine as prescribed, or without a guardian; 12. Pregnant or lactating women, or those planning to become pregnant; 13. There is good evidence of poor response to three previous antipsychotic medications, two of which have different mechanisms of action. (Poor response is defined as severe psychiatric symptoms despite full adherence to the full dose or a full course of treatment.); 14. Patients with contraindications to the antipsychotics recommended in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| triglyceride; | — |
Secondary
| Measure | Time frame |
|---|---|
| total cholesterol;high-density lipoprotein cholesterol;low-density lipoprotein cholesterol;fasting blood glucose;Positive and Negative Symptom Scale score;Personal and Social Performance Scale score;Fasting blood insulin;Mini-mental State Examination score;Montreal Cognitive Assessment scale score;Glucose regulated protein 78;Activation of transcription factor 4;C/EBP homologous protein, CHOP; | — |
Countries
China
Contacts
Public ContactWu Liling
Nanchong Central Hospital
Outcome results
None listed